Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BNY Mellon Names Karen Peetz President - Quick Facts

RELATED NEWS
Trade BK now with 

BNY Mellon (BK: Quote) announced the appointment of Karen Peetz as the President of BNY Mellon. Peetz is currently Vice Chairman and Chief Executive Officer of Financial Markets & Treasury Services. As President, Peetz will lead Global Client Management, Regional Management, Treasury Services and Human Resources.

The company also announced executive appointments. The appointments will be effective Jan. 1.

Timothy Keaney will be named Chief Executive Officer of Investment Services as BNY Mellon aligns its Asset Servicing, Corporate Trust, Depositary Receipts, Global Markets, Global Collateral Services, Broker Dealer Services, and Pershing businesses under his leadership. Keaney is currently Vice Chairman and Chief Executive Officer of Asset Servicing. He will retain his Vice Chairman title.

Brian Shea will be named President of Investment Services and head of BNY Mellon's Global Operations and Technology group. He will also continue in his role as Chief Executive Officer of BNY Mellon's Pershing subsidiary and as head of Broker Dealer and Advisor Services.

Click here to receive FREE breaking news email alerts for The Bank of New York Mellon Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks have moved mostly higher in early trading on Tuesday after ending the previous session roughly flat. The major averages have climbed into positive territory, although there does not seem to be much conviction behind the upward move. Home prices in major U.S. metropolitan areas continued to increase at a slower pace in the month of May, Standard & Poor's revealed in a report released on Tuesday. The report said the S&P/Case-Shiller 20-City Composite Home Price Index increased at an annual rate of 9.3 percent in May compared to the 10.8 percent growth reported for April. Pharmaceutical giant Pfizer, Inc., which was aspiring to buy British drug maker AstraZeneca Plc, reported Tuesday a profit for the second quarter that plunged 79 percent from last year, which reflected hefty gains from animal health business sales. Total revenues declined 2 percent, as it continued to be hurt by generic competition for major drugs.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.